ES3019509T3 - Pharmaceutical composition of glp-1/glp-2 dual agonists - Google Patents

Pharmaceutical composition of glp-1/glp-2 dual agonists Download PDF

Info

Publication number
ES3019509T3
ES3019509T3 ES21836185T ES21836185T ES3019509T3 ES 3019509 T3 ES3019509 T3 ES 3019509T3 ES 21836185 T ES21836185 T ES 21836185T ES 21836185 T ES21836185 T ES 21836185T ES 3019509 T3 ES3019509 T3 ES 3019509T3
Authority
ES
Spain
Prior art keywords
glp
composition
aspects
concentration
dual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21836185T
Other languages
English (en)
Spanish (es)
Inventor
Jesper Skodborg VILLADSEN
Lise Giehm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Application granted granted Critical
Publication of ES3019509T3 publication Critical patent/ES3019509T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES21836185T 2020-12-16 2021-12-16 Pharmaceutical composition of glp-1/glp-2 dual agonists Active ES3019509T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20214562 2020-12-16
PCT/EP2021/086147 WO2022129311A1 (en) 2020-12-16 2021-12-16 Pharmaceutical composition of glp-1/glp-2 dual agonists

Publications (1)

Publication Number Publication Date
ES3019509T3 true ES3019509T3 (en) 2025-05-20

Family

ID=74141274

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21836185T Active ES3019509T3 (en) 2020-12-16 2021-12-16 Pharmaceutical composition of glp-1/glp-2 dual agonists

Country Status (13)

Country Link
US (1) US20240024425A1 (https=)
EP (1) EP4262745B1 (https=)
JP (1) JP7809117B2 (https=)
KR (1) KR20230121823A (https=)
CN (1) CN116710114B9 (https=)
AU (1) AU2021404497A1 (https=)
CA (1) CA3200526A1 (https=)
CL (1) CL2023001747A1 (https=)
ES (1) ES3019509T3 (https=)
IL (1) IL301893A (https=)
MX (1) MX2023006284A (https=)
WO (1) WO2022129311A1 (https=)
ZA (1) ZA202304235B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
IL301892A (en) * 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
JP2024533153A (ja) * 2021-09-03 2024-09-12 ジーランド ファーマ エー/エス 投薬レジーム

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
MXPA04003569A (es) * 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.
ES2373660T3 (es) 2003-11-13 2012-02-07 Novo Nordisk A/S Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
CN104902922B (zh) * 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
AR110300A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
EP3551651B1 (en) * 2016-12-09 2024-03-06 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
SG11202111311WA (en) * 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist

Also Published As

Publication number Publication date
JP7809117B2 (ja) 2026-01-30
IL301893A (en) 2023-06-01
CN116710114B (zh) 2025-11-25
CL2023001747A1 (es) 2024-01-19
CA3200526A1 (en) 2022-06-23
MX2023006284A (es) 2023-06-13
US20240024425A1 (en) 2024-01-25
EP4262745C0 (en) 2025-01-29
ZA202304235B (en) 2025-08-27
JP2023553561A (ja) 2023-12-22
KR20230121823A (ko) 2023-08-21
TW202228764A (zh) 2022-08-01
WO2022129311A1 (en) 2022-06-23
EP4262745B1 (en) 2025-01-29
AU2021404497A1 (en) 2023-06-08
CN116710114A (zh) 2023-09-05
EP4262745A1 (en) 2023-10-25
CN116710114B9 (zh) 2026-01-02

Similar Documents

Publication Publication Date Title
ES2282161T3 (es) Formulaciones de glp-2.
ES3019509T3 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
AU2020290014B2 (en) Pharmaceutical parenteral composition of dual GLP1/2 agonist
JP2025121987A (ja) Glp-1/glp-2デュアルアゴニストの医薬組成物
US20230405088A1 (en) Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
RU2855486C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2855506C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2852511C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
TWI921427B (zh) Glp-1/glp-2雙重促效劑之醫藥組合物
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists